
On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported upbeat second-quarter earnings.
The company posted adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57. The company reported sales of $3.68 billion, up 4% year over year, beating the consensus of $3.29 billion.